Business Wire

CA-VERIMATRIX

Share
Altibox Norway Takes Verimatrix End-to-End Security into the Cloud

Verimatrix , (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Altibox Norway , one of the largest regional telecommunication operators throughout Norway and Denmark, is one of the latest European customers to move its security framework into the Verimatrix Secure Cloud.

The move enables Altibox to take advantage of a flexible Software-as-a-Service (SaaS) model to host Verimatrix Multi-DRM , as well as hosting its existing Verimatrix Video Content Authority System (VCAS™) for IPTV. With the Verimatrix Secure Cloud, Altibox can more easily optimize its end-to-end content security with greater flexibility, ease of scale and lower costs.

Scheduled to be rolled out this year, the transition greatly simplifies Altibox’s management of its popular service offering relied upon by more than half a million subscribers. The cloud-managed Verimatrix Multi-DRM and VCAS for IPTV solutions also keep Altibox in continuous compliance with studio-required changes in security regimes, including MovieLabs specifications for 4K/UHD content.

“A seamless cloud security infrastructure is crucial for continually enhancing our ability to scale as demand grows,” said Jarle Johnsen, Head of TV technology at Altibox. “Moving to a content security management platform in the cloud with a trusted partner like Verimatrix empowers us to better meet growing needs as well as consistently exceed our customers’ expectations – all while attaining well-defined business objectives.”

“We’re happy that Altibox has reached to the cloud and adopted our SaaS model for Multi-DRM and VCAS,” said Asaf Ashkenazi, COO of Verimatrix.” With more of its security framework now managed within the Verimatrix Secure Cloud, Altibox can powerfully protect their revenue from fraud and gain further peace of mind through significantly enhanced reliability.”

To learn more about Verimatrix Multi-DRM and VCAS solutions and the benefits of the Verimatrix Secure Cloud, click here .

About Altibox
Altibox is a unified brand name for Broadband, IPTV and VoIP services distributed in Norway and Denmark with over 35 local Norwegian and 6 Danish FTTH networks. Altibox was set up by Southwestern Norwegian multi-utility firm Lyse Energi in 2002 under the name Lyse Tele. Lyse Tele is made up of the wholly-owned digital TV & broadband provider Altibox AS, and Lyse’s ownership stake in several fibre providers in Norway and Denmark. The national backbone network of Altibox covers all of Norway, from Agder in the south to Finmark in the north. Lyse Tele has 330,000 fibre customers, distributed across Norway. In addition, Altibox provides services to other network operators/owners. In total, more than 600,000 consumers and businesses get their internet and TV entertainment from Altibox. For more information visit www.altibox.no .

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye